white → brown2 → purple3 → black3 → black3 → black3 → black3
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
MDMA
3,4-Methylenedioxymethamphetamine
Ecstasy, Molly, Mandy, Emma, MD
MDMA is a classical entactogen of the substituted amphetamine classcitation needed, first developed in 1912 by the pharmaceutical company Merck. It remained largely obscure until the 1970s, when it gained recognition in underground psychotherapy circles before spreading into nightlife and rave culture. Now one of the most popular recreational drugs worldwide, it is known for producing strong feelings of empathy, emotional closeness, and stimulation. Tablets sold as "ecstasy" frequently contain adulterants or other substances entirely.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~35 mg
Light35-75 mg
Moderate75-125 mg
Strong125-175 mg
Heavy175+ mg
Duration
Onset20-70 minutes
Come Up30-60 minutes
Peak2-3.5 hours
Offset1-2 hours
After Effects2-24 hours
Total3-6 hours
Half-life
7-10 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
The physical effects of MDMA can be broken down into five components all of which progressively intensify proportional to dosage.
Cognitive
The general head space of MDMA is described by many as one of extreme mental stimulation, feelings of love or empathy and powerful euphoria. It contains a large number of typical psychedelic, entactogenic and stimulant cognitive effects.
Visual
The visual effects of MDMA have an occurrence rating that is more selective and less consistent than any of the traditional psychedelics. They can never be guaranteed to manifest themselves but are more likely to occur with chemically pure high dose MDMA experiences, towards the end of the experience and if the user has been smoking marijuana.
Enhancements
MDMA presents an array of visual enhancements which are mild in comparison to traditional psychedelics but still distinctively present.
Geometry
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of psilocin than LSD. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, mostly blue and grey in scheme, glossy in colour, equal in blurred and sharp edges and equal in rounded and angular corners. At higher dosages they are significantly more likely to result in states of Level 7A visual geometry over Level 7B. Many users report an almost menacing feeling, following a sinister and ominous style with a colour scheme that generally consists of greys and blues.
Hallucinatory States
MDMA is capable of producing a unique range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.
Auditory
The auditory effects of MDMA are common in their occurrence and exhibit a partial range of effects.
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Reagent Testing
Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.
white → green3 → blue3 → black3 → black3 → black3 → black3
yellow2 → blue3 → black3 → black3 → black3 → black3
white → black3 → black3 → black3 → black3
Pharmacology
Pharmacodynamics
MDMA functions primarily as a serotonin-norepinephrine-dopamine releasing agent.1 The substance enters monoaminergic neurons via the serotonin, norepinephrine, and dopamine transporters, then reverses their direction to produce efflux of these neurotransmitters into the synapse.1 This releasing action is facilitated by inhibition of vesicular monoamine transporter 2, which increases cytosolic monoamine concentrations available for release, and by agonist activity at trace amine-associated receptor 1, which triggers phosphorylation of the transporters.citation needed MDMA displays approximately tenfold greater affinity for serotonin transporters compared to dopamine and norepinephrine transporters, resulting in predominantly serotonergic effects. Beyond its releasing action, MDMA also exhibits weak partial agonist activity at serotonin 5-HT1 and 5-HT2 receptors, with 5-HT2B receptor signaling appearing necessary for the substance's serotonin-releasing effects. The characteristic entactogenic properties are thought to arise largely from serotonin release and may involve indirect oxytocin secretion mediated by 5-HT1A receptor activation.
Pharmacokinetics
MDMA undergoes extensive hepatic metabolism primarily mediated by CYP2D6, with additional contributions from CYP3A4, CYP2B6, CYP1A2, and CYP2C19.citation needed The principal metabolic pathway involves O-demethylenation to HHMA followed by COMT-catalyzed methylation to HMMA. A secondary pathway proceeds through N-dealkylation to MDA, which then undergoes further metabolism to HHA and HMA. MDMA acts as both a substrate and inhibitor of CYP2D6, with autoinhibition believed to result from interaction between the enzyme and an MDMA metabolite. This autoinhibition produces nonlinear pharmacokinetics at higher doses, potentially resulting in disproportionately elevated plasma concentrations with repeated or escalating doses.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to MDMA's effects develops unusually quickly compared to many other substances. In controlled observations, daily administration of 120-160 mg resulted in complete loss of subjective effects by the fifth or sixth day, with only mild pupil dilation remaining. A notable phenomenon described as 'losing the magic' occurs with repeated use, where the characteristic empathogenic and prosocial effects diminish substantially while stimulant and euphoric properties may persist. Some users report this degradation after as few as 10 experiences, while others maintain full effects through dozens or even hundreds of uses. The empathogenic qualities appear particularly susceptible to tolerance, often fading before other effects.
Baseline Reset
Approximately 2.5 months after a single use in the absence of further consumption. A complete drug-free period of 6 days has been shown to reverse tolerance established through consecutive daily dosing. Most harm reduction guidance recommends waiting 1-3 months between uses, with 4-6 weeks considered an absolute minimum to allow adequate serotonin restoration.
Half Tolerance
Approximately 1 month after a single administration
Cross Tolerance
Dopaminergic stimulants, Serotonergic stimulants
Harm Potential
Addiction & Dependence
Psychological
LowMDMA has moderate to high abuse potential but a low potential for genuine psychological dependence, estimated at lower than 10% and rated three-fourths to four-fifths that of cannabis by expert panels. Compulsive redosing is commonly reported during experiences, and context-dependent psychological dependence may develop when use is linked to specific activities such as parties or raves.
Physical
LowPhysical dependence potential is low, with MDMA often described as not physically addictive. However, approximately 60% of users experience withdrawal symptoms upon cessation, including fatigue, loss of appetite, depression, and difficulty concentrating.citation needed These symptoms are generally mild compared to substances with higher physical dependence potential.
Toxicity
Central Nervous System
Heavy or frequent use, particularly at higher doses, has been associated with neurotoxic damage to serotonergic axon terminals in striatal, hippocampal, prefrontal, and occipital regions;citation needed damage may persist for more than two years but appears partially reversible with abstinence. Typical recreational use at moderate doses and infrequent intervals presents less clear neurotoxicity risk.
Cardiovascular
Heavy or long-term use may increase the risk of valvular heart disease and primary pulmonary hypertension due to chronic activation of serotonin 5-HT2B receptors;citation needed acute cardiovascular stress including elevated heart rate and blood pressure occurs during intoxication.
Hepatic
Liver toxicity has been reported rarely with MDMA use; the liver is stressed during acute intoxication due to extensive hepatic metabolism.
Renal
Kidneys are stressed during MDMA use; individuals with pre-existing kidney disorders may be at higher risk of complications.citation needed
Psychosis Risk
Psychotic episodes are rare but have been reported, typically at high doses or with heavy use. Possible psychological crises requiring hospitalization, including severe panic attacks and psychotic episodes, occur in a small minority of users. At higher doses, delirious external hallucinations may occur, which is not considered a typical or healthy response.
Seizure Risk
Seizures are rare but may occur in susceptible individuals, particularly at higher doses, with redosing, or in physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating. More common in smaller individuals and those with pre-existing epilepsy. A small number of users have reportedly experienced seizures after taking moderate amounts of pure MDMA.
History & Culture
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
UN Convention on Psychotropic Substances 1971 (Schedule I, added February 1986)
By Country
Illegal31
United StatesIllegalClassified as Schedule I under the Controlled Substances Act since July 1, 1985, initially on an emergency basis.79 Manufacturing, buying, possessing, or distributing without a DEA license is illegal. Despite an administrative law judge recommending Schedule III placement to allow medical use, the DEA director overruled and maintained Schedule I status.
By state
Across the 50 states, MDMA is controlled in line with its federal Schedule I status; state schedules verified for 48 states, D.C., Guam, and the Northern Mariana Islands. Alaska places MDMA in its own Schedule IIA rather than a direct Schedule I designation.
AlaskaIllegalAlaska Stat. § 11.71.150(b)(20)80
Alaska lists MDMA in Schedule IIA. MDMA remains a controlled substance under Alaska law, but the state places it in Schedule IIA rather than federal Schedule I.
BelgiumIllegalArrêté royal du 6 septembre 2017 réglementant les substances stupéfiantes et/ou psychotropes13
Possession, production, and sale are prohibited under national drug legislation.
ChileIllegalSupreme Decree No. 405 of 1983, Regulation of Psychotropic Products21
MDMA is listed in List I of the Regulation of Psychotropic Products. The regulation prohibits import, export, production, manufacture, distribution, transport, sale, possession and keeping of List I drugs in Chile, except for authorised scientific research.
Czech RepublicIllegalNařízení vlády č. 463/2013 Sb., o seznamech návykových látek22
Classified as a Schedule I controlled substance under national legislation.
DenmarkIllegalBekendtgørelse om euforiserende stoffer23
Possession, production, and sale are prohibited under Danish drug control legislation.
EgyptIllegalMinister of Health and Population Decision No. 44 of 2026, replacing the schedules annexed to Anti-Narcotics Law No. 182 of 1960242526
MDMA is listed under the phenethylamine group in Schedule 1 annexed to Egypt’s Anti-Narcotics Law No. 182 of 1960. Decision No. 44 of 2026 replaced the law’s schedules and applies from its publication on 17 February 2026. Law No. 182 prohibits importing, exporting, producing, owning, possessing, purchasing, selling, exchanging, transferring, or brokering narcotic substances except as the law permits.
FinlandIllegalFinnish Government Decree 1119/2025 controlled-substance annex27
The amendment to the controlled-substance regulation took effect on 29 December 2025; MDMA is listed in Annex II, Convention Schedule I.
FranceIllegalArrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants28
Classified as a narcotic substance under French law. Possession, purchase, sale, and manufacture are prohibited.
IndiaIllegalNarcotic Drugs and Psychotropic Substances Act, 198531
MDMA is listed in the Schedule's list of psychotropic substances under the Narcotic Drugs and Psychotropic Substances Act, 1985. The Act prohibits production, manufacture, possession, sale, purchase, transport, use, consumption, import, export and transhipment of a psychotropic substance except for authorised medical or scientific purposes.
ItalyIllegalTabelle delle sostanze stupefacenti e psicotrope, DPR 309/199032
Listed in Tabella I of the controlled substances tables (Tabelle delle sostanze stupefacenti e psicotrope). Possession, purchase, and sale are prohibited.
JapanIllegalCabinet Order Designating Narcotics, Narcotic Raw-material Plants, Psychotropic Drugs, and Narcotic and Psychotropic Raw Materials3334
MDMA and its salts are designated narcotics under Cabinet Order No. 238 of 1990, made under the Narcotics and Psychotropics Control Act. The Act restricts import, export, manufacture, transfer, possession and use of narcotics to licensed or otherwise authorised handling.
LatviaIllegalLatvijā kontrolējamo narkotisko vielu, psihotropo vielu un prekursoru saraksti35
Classified as a Schedule I controlled substance. Possession, production, and distribution are illegal.
NorwayIllegalMDMA, listed as “MDMA (ecstacy),” appears in the Narkotikalisten, which forms part of the Narkotikaforskriften in force since 14 February 2013. It is marked “Forbudt etter § 5”; manufacture, acquisition, sale, importation, exportation, storage, possession, and use are prohibited. The Department may make an exception by regulation or individual decision for medical or scientific needs. MDMA is directly named rather than controlled solely through a generic-group provision; psychoactive salts, stereoisomers, esters, and ethers of listed substances are also narcotics under § 3.
PhilippinesIllegalRepublic Act No. 9165 defines MDMA, commonly known as Ecstasy, including its isomers and derivatives. The Act treats Schedule I substances under the 1971 Convention as dangerous drugs and criminalises unauthorised sale, delivery, possession and use of dangerous drugs.
PolandIllegalRegulation of the Minister of Health on the list of psychotropic substances, narcotic drugs and new psychoactive substances5152
MDMA is listed as a Group I-P psychotropic substance in the Polish controlled-substances list. Group I-P psychotropic substances may be manufactured, processed or converted for scientific research only with the prescribed authorisation.
South KoreaIllegalMDMA is listed in Attached Table 4 as a psychotropic drug under Article 2(3)(b) of the Narcotics Control Act. The Act prohibits persons other than authorised narcotics handlers from possessing, using, transporting, importing, exporting, manufacturing, administering, trading in or delivering psychotropic substances.
SwedenIllegalLäkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika64
Possession, production, and sale are prohibited under Swedish drug control legislation.
ThailandIllegalNotification of the Ministry of Public Health Specifying Names and Categories of Narcotics under the Narcotics Code676869
Thailand's Ministry of Public Health lists 3,4-methylenedioxymethamphetamine, also called ecstasy or MDMA, as a Category I narcotic. Category I narcotics may not be imported, exported or possessed without permission from the Ministry of Public Health.
United KingdomIllegalMDMA (3,4-methylenedioxymethamphetamine) has been a Class A controlled drug under the Misuse of Drugs Act 1971 since 1977. Unauthorised possession, production, supply, importation and exportation are offences. It is also in Schedule 1 to the Misuse of Drugs Regulations 2001, so lawful access for research or other special purposes requires a Home Office licence.
Prescription1
AustraliaPrescription onlyLegal / decriminalized2
PeruDecriminalizedCódigo Penal (Decreto Legislativo Nº 635), artículo 299, modificado por Decreto Legislativo Nº 1592464748
MDMA is listed in Lista IB as a prohibited-use controlled substance in Peru. Article 299 makes possession of up to 250 milligrams of ecstasy containing MDMA non-punishable when it is for the holder’s own immediate consumption. The exception does not apply to possession of two or more types of toxic drug; manufacture, trafficking, and possession for illegal use remain criminal offences.
References
Source Pages
Bluelight: MDMA Threshold Dose Discussion (2019)
Disregard Everything I Say
Drug Users Bible by Dominic Milton Trott
DrugBank
Erowid- Erowid: MDMA Basics
- Erowid: MDMA Dosage
- Erowid: MDMA FAQ
- Erowid: MDMA Neurotoxicity Article (Baggott)
Isomer Design (TiHKAL/PiHKAL)
PsychonautWiki
The Drug Classroom
TripSit Factsheets- TripSit Wiki
- TripSit: Drug Combinations Chart
Wikipedia
Citations
- Austen B. Casey, & Boris D. Heifets. (October 2025). History, pharmacology and therapeutic mechanisms of 3,4-methylenedioxymethamphetamine (MDMA). Br J Pharmacol. https://doi.org/10.1111/bph.7022512
- Lee E. Dunlap, Anne M. Andrews, & David E. Olson. (October 2018). Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chemical Neuroscience, 9(10), 2408–2427. https://doi.org/10.1021/acschemneuro.8b00155123
- Roland W. Freudenmann, Florian Öxler, & Sabine Bernschneider‐Reif. (August 2006). The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction, 101(9), 1241–1245. https://doi.org/10.1111/j.1360-0443.2006.01511.x12345
- Jerry Meyer. (2013). 3,4-methylenedioxymethamphetamine (MDMA): current perspectives. Substance Abuse and Rehabilitation, 4, 83–99. https://doi.org/10.2147/sar.s372581
- Lester Grinspoon, M.d., Petitioner, v. Drug Enforcement Administration, Respondent, 828 F.2d 881 (1st Cir. 1987). Justia Law (n.d.). https://law.justia.com/cases/federal/appellate-courts/F2/828/881/368975/1
- FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD. (n.d.). https://maps.org/news/media/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials/1
- Therapeutic Goods (Poisons Standard—July 2023) Instrument 2023. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2023L008641
- Therapeutic Goods (Poisons Standard—July 2023) Instrument 2023. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2024L01036/asmade/2024-08-20/es/original/pdf1
- Decriminalisation of low-level drug possession in the ACT. (n.d.). https://hugolawgroup.com.au/insights/decriminalisation-of-low-level-drug-possession-in-the-act/1
Further Reading
EMCDDA: MDMA Drug Profile
Kalant 2001 - Pharmacology & Toxicology of Ecstasy
MAPS MDMA-Assisted Therapy Phase 3 Trial (2021)
MDMA and Bipolar Disorder Interaction- MDMA Clinically Relevant Drug Interactions with MAOIs
- Parrott 2013 - MDMA Neurotoxicity Review
Reddit: r/researchchemicals MDMA Dosing Discussions
RollSafe MDMA Wiki- Serotonin Syndrome Case Series (FAERS 2022)
- Serotonin Syndrome Overview
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
5 August 2026
Lyrea · Updated the article
25 March 2026
Lyrea · Updated the article · also 2C-B, Alprazolam, DOM
Josie Kins · Updated the article
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the MDMA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
